Phio Pharmaceuticals Corp.
PHIO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001533040
In the last 90 days, Phio Pharmaceuticals Corp. insiders filed 9 open-market purchases and 0 sales; 24 institutions reported holding it in 13F filings for Q2 2026, worth $662.6K in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 11, 2026
- $9.72M
- Insider buysLast 90 days, $104.8K in total
- 9
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, 0 vs. previous quarter
- 24
- 13F valueReported value at the end of Q2 2026
- $662.6K
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$8.70M
- No comparable prior period
- Free cash flow, FY2025
- -$7.99M
- No comparable prior period
- Revenue, Q3 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 86.3K
- Shares sold short
- Change
- −50.0K
- −36.7% vs. previous
- Days to cover
- 1.49
- At average daily volume
Superinvestors holding PHIO, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding PHIO at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Phio Pharmaceuticals Corp. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 12, 2026 (view filing)9:52 AM ET | Nov 10-11 | 2 days | Deming David HDirector | PPurchaseCommon Stock, $.0001 par value | +12.0K | $0.8389 | +$10.1K | +31.7%49.8K after | 2 lots |
| Nov 10, 2026 (view filing)11:18 AM ET | Nov 9 | 1 day | Plott Ronald ToddDirector | PPurchaseCommon Stock, $.0001 par value | +18.3K | $0.83 | +$15.2K | +43.6%60.3K after | |
| Nov 10, 2026 (view filing)11:17 AM ET | Nov 9 | 1 day | Bitterman Robert JChairman, Pres. & CEO | PPurchaseCommon Stock, $.0001 par value | +25.0K | $0.82 | +$20.5K | +3.3%789.9K after | |
| Sep 30, 2026 (view filing)4:01 PM ET | Sep 28-29 | 2 days | Plott Ronald ToddDirector | PPurchaseCommon Stock, $.0001 par value | +10.0K | $1.04 | +$10.3K | +31.3%42.0K after | 2 lots |
| Sep 25, 2026 (view filing)4:01 PM ET | Sep 24 | 1 day | Bradford Patricia ADirector | PPurchaseCommon Stock, $.0001 par value | +6.50K | $1.01 | +$6.58K | +11.3%64.2K after | |
| Sep 23, 2026 (view filing)4:01 PM ET | Sep 22 | 1 day | Bitterman Robert JChairman, Pres. & CEO | PPurchaseCommon Stock, $.0001 par value | +2.00K | $1.03 | +$2.06K | +0.6%364.9K after | |
| Sep 16, 2026 (view filing)4:01 PM ET | Sep 15 | 1 day | Bradford Patricia ADirector | PPurchaseCommon Stock, $.0001 par value | +12.0K | $1.03 | +$12.4K | +26.3%57.7K after | |
| Aug 20, 2026 (view filing)8:30 AM ET | Aug 19 | 1 day | Plott Ronald ToddDirector | PPurchaseCommon Stock, $.0001 par value | +15.0K | $1.14 | +$17.1K | New position15.0K after | |
| Aug 19, 2026 (view filing)4:01 PM ET | Aug 18 | 1 day | Bitterman Robert JChairman, Pres. & CEO | PPurchaseCommon Stock, $.0001 par value | +10.0K | $1.06 | +$10.6K | +2.4%431.4K after | |
| Jun 29, 2026 (view filing) | Jun 26 | 3 days | Bitterman Robert JChairman, Pres. & CEO | PPurchaseCommon Stock, $.0001 par value | +10.0K | $0.99 | +$9.90K | +2.4%421.4K after |
Top 10 13F holders, Q2 2026
See all 24 holdersThe largest institutional positions in Phio Pharmaceuticals Corp. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Jane Street Group, LLC | 117,755 | $120.7K | 0.00% | −1,434−1.2% | Reduced |
| Geode Capital Management, LLC | 114,574 | $117.4K | 0.00% | −32,680−22.2% | Reduced |
| Vanguard Capital Management LLC | 94,262 | $96.6K | 0.00% | +14,409+18.0% | Added |
| Nomura Asset Management International Inc. | 50,000 | $51.0K | 0.00% | +50,000 | New |
| Cetera Investment Advisers | 47,500 | $48.7K | 0.00% | +2,500+5.6% | Added |
| Citadel Advisors LLC | 47,150 | $48.3K | 0.00% | +47,150 | New |
| Vanguard Fiduciary Trust Co | 38,169 | $39.1K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 27,768 | $28.5K | 0.00% | +4,010+16.9% | Added |
| Two Sigma Investments, LP | 21,501 | $22.0K | 0.00% | −10,994−33.8% | Reduced |
| XTX Topco Ltd | 18,475 | $18.9K | 0.00% | −6,393−25.7% | Reduced |
Holders of 5% or more of PHIO
See all 2 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Phio Pharmaceuticals Corp..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| CVI Investments, Inc. | 13G/A | 9.90%1.19M shares | 0.00 ppfrom 9.90% | Feb 16, 20215 filings | Feb 17, 2026 | SEC |
| Intracoastal Capital, LLC | 13G/A | 9.10%1.14M shares | +2.10 ppfrom 7.00% | Jan 29, 20219 filings | Feb 13, 2026 | SEC |